Global Following the appointment of new boards at the US innovative pharma industry body PhRMA, and its European counterpart EFPIA, it is global group the IFPMA’s turn to reveal a new CEO leadership team, with appointees from Pfizer, Roche and Daiichi Sankyo. As the industry’s biggest global trade group that…
Global After an almost 20-year career in Big Pharma culminating in a role as president of AstraZeneca UK, Lisa Anson took the leap into the biotech world to lead what at the time was an ailing business, UK-based Redx Pharma. Having transformed Redx into the thriving biotech that it is today,…
Global Sarah Pope Miksinski, executive director/CMS regulatory affairs, and Gregory Rullo, senior director regulatory affairs, at AstraZeneca discuss the need for common ground among regulators and industry when it comes to patient centricity and for strategic leadership to address differing regulatory control-strategy requirements. In today’s increasingly complex and intricate pharmaceutical landscape,…
Global Swiss pharma giant, Roche, has announced a change in leadership that will see Severin Schwan replaced by diagnostics division head, Thomas Schinecker, after a 14-year stint as CEO. Schinecker, who became a contender for the role by leading the company’s efforts in developing a COVID-19 test kit, growing sales by…
United Kingdom After several scandals that revealed longstanding deficiencies and a continual churn of executive staff, a recent independent review of leadership in the National Health Service (NHS) has uncovered a lack of consistency and coordination as well as cases of discrimination within the system. As a result of the report, the…
LatAm Writing in the March edition of DIA’s Global Forum magazine, the University of Southern California’s Viktoria Magyar looks at how Latin American regulatory bodies adapted to the COVID-19 pandemic and what some of its longer-term impacts on regulatory activities in the region might be. Driven by increasing workloads, limited…
China Portuguese national Isabel Afonso, a Novartis and Sandoz veteran of almost 20 years, has taken on a new role as general manager of Novartis’ highly strategic oncology franchise in China as of November 2021. Since first joining the company back in 2002, Afonso held a variety of roles IT…
China Hot on the heels of a USD 120 million fundraising round, Shanghai-based EpimAb Biotherapeutics is now looking towards a 2022 IPO with the aim of becoming a globally competitive player in the bispecific antibody field. The Series C financing round means that the company has raised over USD 220…
Spain The latest from Spanish pharma, including the wide swathe of COVID-19 syringes, vaccines, masks, and tests being produced in the country, Grifols’ Egyptian entry, a new generation of leadership at Almirall, and Esteve’s European Expansion. Weapons “made in Spain” in the war against Covid-19 (La Razón – Spanish) https://www.larazon.es/salud/20201214/iecgoyhkpfeifhlfgpracvgtci.html…
Japan Founded by Toyoji Naito in December 1941, in just under 80 years, Eisai has become a leading global biopharma player, with pharmaceutical revenues of USD 5.4 billion in 2019. The company’s central philosophy of human health care (hhc) was introduced in 1992 by current director, representative corporate officer and…
USA David H. Crean, managing director for Objective Capital Partners, provides insights on US innovation and long term sustainability. The life sciences industry within the United States makes significant contributions to both America’s health and economy and is a leader in R&D and innovation based on numerous proxies including patents received,…
Switzerland While Switzerland has Europe’s second-highest proportion of women in the workforce, it trails global standards on gender diversity in boardrooms and in management positions. However, this situation is changing and two of Switzerland’s most important pharma affiliates are at the forefront of a new wave of diverse Swiss leadership teams.…
See our Cookie Privacy Policy Here